相关临床试验
40
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1910
进行中（未招募）
1
2.5%
已完成
20
50.0%
招募中
7
17.5%
终止
6
15.0%
Unknown
4
10.0%
撤回
2
5.0%
暂无批准数据
- Recent clinical trials demonstrate sustained efficacy of newer biologics like bimekizumab and risankizumab in treating psoriatic arthritis, expanding treatment options beyond traditional TNF inhibitors. - Dr. Philip Mease highlights the growing arsenal of biologics targeting IL-17 and IL-23 pathways, offering multiple therapeutic options for maintaining minimal disease activity in PsA patients. - Long-term safety data and comparative studies are strengthening the evidence base for biologic sequencing, providing clinicians with more confidence in cycling between different mechanisms when treatment effects diminish.
- Leading research reveals that axial inflammation affects up to 40% of psoriatic arthritis patients, prompting efforts to establish clearer diagnostic criteria based on clinical features, imaging findings, and genetic markers. - Phase 2 ARGO study of sonelokimab and phase 4 STAR study of guselkumab are among key upcoming trials investigating new treatment options for axial psoriatic arthritis. - Collaborative efforts between major rheumatology research groups are developing new classification criteria for axial PsA to improve disease understanding and treatment approaches.
